A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

The requested reference [a69904ae726f6819ffe0d5cee51ce5e92e4068de] no longer exists in our database. It has been replaced by the current reference: [61d3bcdd476f4b8bb71ca9c21738b0f937975245]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The goal of this Phase 2 Alzheimer\'s study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.
Epistemonikos ID: 96b4669881f2dca5c7cf14fc8b91a31cc448afcb
First added on: May 13, 2024